# Women's Oncology Program - WON

> **NIH NIH P30** · UNIVERSITY OF VIRGINIA · 2020 · $56,265

## Abstract

WOMEN'S ONCOLOGY (WON) – PROJECT SUMMARY/ABSTRACT 
The Women's Oncology Program (WON) aims to stimulate high quality basic, translational, and clinical 
research and trials in women's cancers through collaborations, program interactions, information sharing, and 
faculty recruitment, and to translate the research findings into cutting edge diagnostics and treatments for 
cancer. Leaders of the Women's Oncology program include Margaret A. Shupnik, PhD, Professor of 
Medicine and Physiology, an expert in molecular endocrinology and estrogen receptor action; Susan C. 
Modesitt. MD, Professor of Obstetrics and Gynecology, an expert in gynecology-oncology clinical trials; and 
Joellen M. Schildkraut, PhD, MPH Professor of Public Health Sciences, an expert in the genetics and 
epidemiology of women's cancers, particularly breast and ovarian cancer. WON represents a wide variety of 
intellectual, technical, and clinical expertise with 25 members from 10 different basic science and clinical 
departments in the School of Medicine and School of Engineering and Applied Science, and 3 associate 
members. Cancer Center support for faculty recruitment and retention, forums for information exchange such 
as the Cancer Center Seminar Series, Women's Oncology monthly research meetings and Program Retreat, 
Cancer Center pilot research funds, and support for and from our Shared Resources have enabled the 
success of our research programs, which have become increasingly cancer-focused and interactive. The high 
quality of the resulting science resulted in numerous high impact publications, including 22% inter- 
programmatic and 18% intra-programmatic publications over the past 5 years. Current funding is over $4.5M, 
including $2M in NCI funding, and patient accrual was robust for patients with Breast (17.5%) and Ovarian 
(45.8%) cancers in 2015. With over 300,000 new diagnoses of these cancers yearly in the United States, it 
remains essential to develop new treatments for cancers resistant to current therapeutic approaches, methods 
for early detection and prognostic indicators for responses, and methods to assess risk and prevent breast and 
gynecological cancers. The WON program has developed specific aims and transdisciplinary groups of 
investigators to tackle these critical issues in women's cancers. Aim 1: To investigate pathways of 
therapeutic resistance in women's cancers and identify prognostic indicators and new molecular 
targets. Aim 2: To understand how dysregulation of metabolism and obesity contribute to women's 
cancers and identify potential new therapeutic targets. Aim 3. To identify behavioral, hormonal and 
genetic risks for women's cancers, and improve detection methods for these cancers. Each aim 
includes basic, translational and clinical research and trials that cut across all women's cancers.

## Key facts

- **NIH application ID:** 9854925
- **Project number:** 5P30CA044579-29
- **Recipient organization:** UNIVERSITY OF VIRGINIA
- **Principal Investigator:** Roger T. Anderson
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $56,265
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9854925

## Citation

> US National Institutes of Health, RePORTER application 9854925, Women's Oncology Program - WON (5P30CA044579-29). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9854925. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*